Erbitux (ImClone Systems Inc) en es it fr

Erbitux (ImClone Systems Inc) Brand names, Erbitux (ImClone Systems Inc) Analogs

Erbitux (ImClone Systems Inc) Brand Names Mixture

  • Actinac Pwr (Allantoin + Butoxyethyl Nicotinate + Chloramphenicol + Hydrocortisone Acetate + Sulfur)
  • Actinac Pws (Allantoin + Butoxyethyl Nicotinate + Chloramphenicol + Hydrocortisone Acetate + Sulfur)
  • Chlorasone (Chloramphenicol + Prednisolone Acetate)
  • Elase Chloromycetin Ont (Chloramphenicol + Deoxyribonuclease Pancreatic + Fibrinolysin)
  • Liquichlor (Chloramphenicol + Prednisolone + Squalane + Tetracaine)
  • Ophthocort Ont (Chloramphenicol + Hydrocortisone Acetate + Polymyxin B)
  • Sopamycetin/Hc Ointment (Chloramphenicol + Hydrocortisone Acetate)
  • Sopamycetin/Hc Ont (Chloramphenicol + Hydrocortisone Acetate)
  • Sopamycetin/Hc Susp (Chloramphenicol + Hydrocortisone Acetate)
  • Zoomycetine Spray (Chloramphenicol + Isopropyl Alcohol + Methyl Violet)

Erbitux (ImClone Systems Inc) Chemical_Formula

C6484H10042N1732O2023S36

Erbitux (ImClone Systems Inc) RX_link

http://www.rxlist.com/cgi/generic3/erbitux.htm

Erbitux (ImClone Systems Inc) fda sheet

Erbitux_(ImClone_Systems_Inc) FDA

Erbitux (ImClone Systems Inc) msds (material safety sheet)

Erbitux (ImClone Systems Inc) Synthesis Reference

sequence listed in Goldstein N. I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1: 1311-1318, 1995.) patent 6,217,866

Erbitux (ImClone Systems Inc) Molecular Weight

145781.6

Erbitux (ImClone Systems Inc) Melting Point

61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).

Erbitux (ImClone Systems Inc) H2O Solubility

No information avaliable

Erbitux (ImClone Systems Inc) State

Liquid

Erbitux (ImClone Systems Inc) LogP

-0.413

Erbitux (ImClone Systems Inc) Dosage Forms

Solution (IV Infusion)

Erbitux (ImClone Systems Inc) Indication

For treatment of metastatic colorectal cancer

Erbitux (ImClone Systems Inc) Pharmacology

Used in the treatment of colorectal cancer, Erbitux binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Erbitux competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor??“alpha. Binding of Erbitux to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production.

Erbitux (ImClone Systems Inc) Absorption

No information avaliable

Erbitux (ImClone Systems Inc) side effects and Toxicity

No information avaliable

Erbitux (ImClone Systems Inc) Patient Information

No information avaliable

Erbitux (ImClone Systems Inc) Organisms Affected

Humans and other mammals